vimarsana.com

Latest Breaking News On - Institutional investors weigh in on fusion pharmaceuticals - Page 1 : vimarsana.com

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) Receives $20 25 Consensus Target Price from Analysts

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have earned a consensus rating of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat reports. Thirteen equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month […]

Fusion Pharmaceuticals (NASDAQ:FUSN) Rating Lowered to Market Perform at Leerink Partnrs

Leerink Partnrs downgraded shares of Fusion Pharmaceuticals (NASDAQ:FUSN – Free Report) from an outperform rating to a market perform rating in a research note released on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for Fusion Pharmaceuticals’ Q1 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.40) EPS and FY2025 earnings at ($1.42) EPS. Other […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.